RxDoctor Payments Data

Carmela San Luis, MD

Neurology · Corning, NYNPI 1447600721

Payments from drug & device makers

$1,689in general payments, 2019–2025

Across 73 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$199
  • AbbVie$141
  • Biogen$125
  • Catalyst Pharmaceuticals, Inc.$125
  • Teva Pharmaceuticals USA, Inc.$107
  • Alnylam Pharmaceuticals Inc.$106
  • plus $886 from 19 others

What the payments were for

  • Speaking & faculty fees$342%
  • Food & beverage$1,56493%
  • Education$915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,689 in reported general payments places this provider in the 50th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$43,921
Medicare patients
210
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe87$63,129
UbrelvyUbrogepant48$54,119
Nurtec OdtRimegepant Sulfate44$52,327
FycompaPerampanel21$26,534
XcopriCenobamate11$21,457
QuliptaAtogepant13$16,533
VimpatLacosamide16$14,064
Ajovy SyringeFremanezumab-Vfrm12$8,851
Pregabalin112$6,524
ReyvowLasmiditan Succinate15$6,469
Levetiracetam141$4,952
Divalproex Sodium ErDivalproex Sodium123$4,383
Carbidopa-LevodopaCarbidopa/Levodopa123$4,209
Carbamazepine ErCarbamazepine55$4,008
Carbidopa-Levodopa ErCarbidopa/Levodopa56$3,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$141$70,65261 claims
PfizerNurtec Odt$199$52,32744 claims
Eisai Inc.Fycompa$15$26,53421 claims
SK Life Science, Inc.Xcopri$82$21,45711 claims
Lilly USA, LLCReyvow$52$6,46915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,623 neurology providers in New York.

Other neurology in Corning

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →